Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

This study has been terminated.
(The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00667810
First received: April 24, 2008
Last updated: January 8, 2013
Last verified: January 2013
  Purpose

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.


Condition Intervention Phase
Alzheimer Disease
Drug: bapineuzumab
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Trial Of Bapineuzumab In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Alzheimer's Disease Assessment Scale-Cognitive Subscale total score [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]
  • Disability Assessment for Dementia total score [ Time Frame: 78 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Brain Amyloid Burden [ Time Frame: 71 Weeks ] [ Designated as safety issue: No ]
  • CSF Phospho-tau level [ Time Frame: 71 Weeks ] [ Designated as safety issue: No ]
  • MRI Brain Boundry Shift Integral [ Time Frame: 71 Weeks ] [ Designated as safety issue: No ]
  • Divergence of effect [ Time Frame: 39 Weeks ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: 78 Weeks ] [ Designated as safety issue: No ]
  • Dependence Scale [ Time Frame: 78 Weeks ] [ Designated as safety issue: No ]
  • Proportion of Responders [ Time Frame: 78 Weeks ] [ Designated as safety issue: No ]
  • Clinical Dementia Rating Sum of Boxes [ Time Frame: 78 Weeks ] [ Designated as safety issue: No ]

Enrollment: 835
Study Start Date: May 2008
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bapineuzumab 0.5 mg/kg Drug: bapineuzumab
Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Other Name: AAB-001
Experimental: Bapineuzumab 1.0 mg/kg Drug: bapineuzumab
Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Other Name: AAB-001
Placebo Comparator: Placebo Drug: placebo
Placebo will be administered by IV infusion approximately every 13 weeks through week 65.

  Eligibility

Ages Eligible for Study:   50 Years to 88 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination (MMSE) score of 16-26, and brain magnetic resonance imaging (MRI) consistent with the diagnosis of AD
  • Concurrent use of cholinesterase inhibitor or memantine allowed, if stable
  • Caregiver will participate and be able to attend clinic visits with patient

Exclusion Criteria:

  • Significant neurological disease other than AD
  • Major psychiatric disorder
  • Contraindication to undergo brain MRI [e.g., pacemaker, cerebrospinal fluid (CSF) shunt, or foreign metal objects in the body]
  • Women of childbearing potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00667810

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294
United States, Arizona
Pfizer Investigational Site
Goodyear, Arizona, United States, 85395
Pfizer Investigational Site
Phoenix, Arizona, United States, 85006
Pfizer Investigational Site
Phoenix, Arizona, United States, 85050
Pfizer Investigational Site
Phoenix, Arizona, United States, 85032
United States, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
Pfizer Investigational Site
Costa Mesa, California, United States, 92626
Pfizer Investigational Site
Fresno, California, United States, 93720
Pfizer Investigational Site
Loma Linda, California, United States, 92354
Pfizer Investigational Site
Long Beach, California, United States, 90806
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Francisco, California, United States, 94109
United States, Colorado
Pfizer Investigational Site
Boulder, Colorado, United States, 80304
Pfizer Investigational Site
Denver, Colorado, United States, 80218
United States, Connecticut
Pfizer Investigational Site
Danbury, Connecticut, United States, 06810
Pfizer Investigational Site
Fairfield, Connecticut, United States, 06824
Pfizer Investigational Site
Greenwich, Connecticut, United States, 06830
Pfizer Investigational Site
New Haven, Connecticut, United States, 06510
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Pfizer Investigational Site
New Haven, Connecticut, United States, 06519
Pfizer Investigational Site
New Haven, Connecticut, United States, 06520
Pfizer Investigational Site
Norwalk, Connecticut, United States, 06851
Pfizer Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Florida
Pfizer Investigational Site
Atlantis, Florida, United States, 33462
Pfizer Investigational Site
Bradenton, Florida, United States, 34205
Pfizer Investigational Site
Delray Beach, Florida, United States, 33445
Pfizer Investigational Site
Hallandale Beach, Florida, United States, 33009
Pfizer Investigational Site
Ocala, Florida, United States, 34481
Pfizer Investigational Site
Ocala, Florida, United States, 34471
Pfizer Investigational Site
Orlando, Florida, United States, 32806
Pfizer Investigational Site
Palm Beach Gardens, Florida, United States, 33418
Pfizer Investigational Site
Port Charlotte, Florida, United States, 33952
Pfizer Investigational Site
Sarasota, Florida, United States, 34243
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33407
United States, Georgia
Pfizer Investigational Site
Decatur, Georgia, United States, 30033
Pfizer Investigational Site
Lawerenceville, Georgia, United States, 30045
Pfizer Investigational Site
Lawrenceville, Georgia, United States, 30046
United States, Illinois
Pfizer Investigational Site
Elk Grove Village, Illinois, United States, 60007
Pfizer Investigational Site
Peoria, Illinois, United States, 61606
Pfizer Investigational Site
Peoria, Illinois, United States, 61636
Pfizer Investigational Site
Peoria, Illinois, United States, 61602
Pfizer Investigational Site
Springfield, Illinois, United States, 62702
Pfizer Investigational Site
Springfield, Illinois, United States, 62781
United States, Indiana
Pfizer Investigational Site
Elkhart, Indiana, United States, 46514
Pfizer Investigational Site
Mishawaka, Indiana, United States, 46545
United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States, 67207
Pfizer Investigational Site
Wichitia, Kansas, United States, 67205
United States, Kentucky
Pfizer Investigational Site
Paducah, Kentucky, United States, 42003
United States, Louisiana
Pfizer Investigational Site
Lake Charles, Louisiana, United States, 70629
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70114
Pfizer Investigational Site
Shreveport, Louisiana, United States, 71104
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
Pfizer Investigational Site
Boston, Massachusetts, United States, 02118
Pfizer Investigational Site
Boston, Massachusetts, United States, 021147
Pfizer Investigational Site
Newton, Massachusetts, United States, 02459
Pfizer Investigational Site
Pittsfield, Massachusetts, United States, 01201
Pfizer Investigational Site
Springfield, Massachusetts, United States, 01104
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-5872
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48110
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109
Pfizer Investigational Site
East Lansing, Michigan, United States, 48824
Pfizer Investigational Site
Lansing, Michigan, United States, 48910
United States, Mississippi
Pfizer Investigational Site
Flowood, Mississippi, United States, 39232
Pfizer Investigational Site
Hattiesburg, Mississippi, United States, 39401
United States, Missouri
Pfizer Investigational Site
Kansas City, Missouri, United States, 64114
United States, New Jersey
Pfizer Investigational Site
Eatontown, New Jersey, United States, 07724
Pfizer Investigational Site
Manchester, New Jersey, United States, 08759
Pfizer Investigational Site
Toms River, New Jersey, United States, 08755
United States, New York
Pfizer Investigational Site
Brewster, New York, United States, 10509
Pfizer Investigational Site
Liverpool, New York, United States, 13088
Pfizer Investigational Site
Rochester, New York, United States, 14642
Pfizer Investigational Site
Rochester, New York, United States, 14620
United States, North Carolina
Pfizer Investigational Site
Charlotte, North Carolina, United States, 28211
Pfizer Investigational Site
Hickory, North Carolina, United States, 28602
Pfizer Investigational Site
Hickory, North Carolina, United States, 28601
Pfizer Investigational Site
Raleigh, North Carolina, United States, 27607
United States, Ohio
Pfizer Investigational Site
Columbus, Ohio, United States, 43210
Pfizer Investigational Site
Toledo, Ohio, United States, 43623
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97225
United States, Pennsylvania
Pfizer Investigational Site
Abington, Pennsylvania, United States, 19001
Pfizer Investigational Site
Jenkintown, Pennsylvania, United States, 19046
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19104
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15206
Pfizer Investigational Site
Willow Grove, Pennsylvania, United States, 19090
United States, Rhode Island
Pfizer Investigational Site
East Providence, Rhode Island, United States, 02914
Pfizer Investigational Site
Pawtucket, Rhode Island, United States, 02861
Pfizer Investigational Site
Providence, Rhode Island, United States, 02906
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
Pfizer Investigational Site
North Charleston, South Carolina, United States, 29406
United States, Tennessee
Pfizer Investigational Site
Cordova, Tennessee, United States, 38018
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75214
Pfizer Investigational Site
San Antonio, Texas, United States, 78231
Pfizer Investigational Site
San Antonio, Texas, United States, 78258
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
Pfizer Investigational Site
Wichita Falls, Texas, United States, 76309
United States, Vermont
Pfizer Investigational Site
Bennington, Vermont, United States, 05201
United States, Virginia
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22908
Pfizer Investigational Site
Charlottesville, Virginia, United States, 22903
Argentina
Pfizer Investigational Site
Buenos Aires, Argentina, 1431
Pfizer Investigational Site
Buenos Aires, Argentina, C1181ACH
Australia, New South Wales
Pfizer Investigational Site
Gosford, New South Wales, Australia, 2250
Pfizer Investigational Site
Hornsby, New South Wales, Australia, 02077
Australia, South Australia
Pfizer Investigational Site
Woodville South, South Australia, Australia, 5011
Australia, Victoria
Pfizer Investigational Site
Ballarat, Victoria, Australia, 3353
Pfizer Investigational Site
West Heidelberg, Victoria, Australia, 3081
Australia
Pfizer Investigational Site
Adelaide SA, Australia, 5000
Pfizer Investigational Site
Nedlands, Australia, 6009
Belgium
Pfizer Investigational Site
Antwerpen, Belgium, 2020
Pfizer Investigational Site
Brugge, Belgium, 8000
Pfizer Investigational Site
Bruxelles, Belgium, 1200
Pfizer Investigational Site
Edegem, Belgium, 2650
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Roeselare, Belgium, 8800
Canada, Ontario
Pfizer Investigational Site
North York, Ontario, Canada, M6M 3Z5
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1N 5C8
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Pfizer Investigational Site
Toronto, Ontario, Canada, M3B 2S7
Canada, Quebec
Pfizer Investigational Site
L'Ancienne-Lorette, Quebec, Canada, G2E 2X1
Pfizer Investigational Site
Montreal, Quebec, Canada, H1T 2M4
Pfizer Investigational Site
Sherbrooke, Quebec, Canada, J1H 1Z1
Canada
Pfizer Investigational Site
Quebec, Canada, G3K 2P8
Chile
Pfizer Investigational Site
Santiago, Chile
Pfizer Investigational Site
Santiago, Chile, 7530193
Croatia
Pfizer Investigational Site
Zagreb, Croatia, 10000
Finland
Pfizer Investigational Site
Kuopio, Finland, FIN-70210
Pfizer Investigational Site
Turku, Finland, 20520
Former Serbia and Montenegro
Pfizer Investigational Site
Belgrade, Former Serbia and Montenegro, 11000
Pfizer Investigational Site
Kragujevac, Former Serbia and Montenegro, 34000
France
Pfizer Investigational Site
Rennes, Cedex, France, 35064
Pfizer Investigational Site
Amiens, France, 80054
Pfizer Investigational Site
Bordeaux, France, 33076
Pfizer Investigational Site
Bron, France, 69677
Pfizer Investigational Site
Caen, France, 14033
Pfizer Investigational Site
Colmar, France, 68024
Pfizer Investigational Site
Dijon, France, 21000
Pfizer Investigational Site
Lille, France, 59037
Pfizer Investigational Site
Marseille, France, 13009
Pfizer Investigational Site
Marseille, France, 13885
Pfizer Investigational Site
Montpellier, France, 34295
Pfizer Investigational Site
Nantes - Saint Herblain, France, 44093
Pfizer Investigational Site
Nice, France, 06000
Pfizer Investigational Site
Paris, France, 75013
Pfizer Investigational Site
Paris Cedex 13, France, 75651
Pfizer Investigational Site
Poitiers, France, 86021
Pfizer Investigational Site
Reims, France, 51000
Pfizer Investigational Site
Rouen, France, 76031
Pfizer Investigational Site
Toulouse, France, 31059
Pfizer Investigational Site
Toulouse, France, 31300
Germany
Pfizer Investigational Site
Berlin, Germany, 14050
Pfizer Investigational Site
Bochum, Germany, 44791
Pfizer Investigational Site
Offenburg, Germany, 77654
Italy
Pfizer Investigational Site
Ancona, Italy, 60020
Pfizer Investigational Site
Catania, Italy, 95126
Pfizer Investigational Site
Chieti, Italy, 66013
Pfizer Investigational Site
Firenze, Italy, 50131
Pfizer Investigational Site
Milano, Italy, 20127
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Milano, Italy, 20133
Pfizer Investigational Site
Monza, Italy, 20052
Pfizer Investigational Site
Roma, Italy, 00179
Pfizer Investigational Site
Roma, Italy, 00128
Pfizer Investigational Site
Siena, Italy, 53100
Japan
Pfizer Investigational Site
Nagoya, Aichi,, Japan
Pfizer Investigational Site
Ota-ku, Tokyo, Japan
Pfizer Investigational Site
Aichi, Japan
Pfizer Investigational Site
Chiba, Japan
Pfizer Investigational Site
Fukuoka, Japan
Pfizer Investigational Site
Gunma, Japan
Pfizer Investigational Site
Hiroshima, Japan
Pfizer Investigational Site
Hyogo, Japan
Pfizer Investigational Site
Iwate, Japan
Pfizer Investigational Site
Kagawa, Japan
Pfizer Investigational Site
Kanagawa, Japan
Pfizer Investigational Site
Kyoto, Japan
Pfizer Investigational Site
Nagano, Japan
Pfizer Investigational Site
Niigata, Japan
Pfizer Investigational Site
Okayama, Japan
Pfizer Investigational Site
Osaka, Japan
Pfizer Investigational Site
Shizuoka, Japan
Pfizer Investigational Site
Tokyo, Japan
Korea, Republic of
Pfizer Investigational Site
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
Pfizer Investigational Site
Seoul, Korea, Republic of, 143-729
Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico, 64000
Pfizer Investigational Site
Aguascalientes, Mexico, 20127
Netherlands
Pfizer Investigational Site
's-Hertogenbosch, Netherlands, 5223 GZ
Pfizer Investigational Site
Amsterdam, Netherlands, 1081 HV
Pfizer Investigational Site
Breda, Netherlands, 4818 CK
Pfizer Investigational Site
Eindhoven, Netherlands, 5623 EJ
Pfizer Investigational Site
Leeuwarden, Netherlands, 8934 AD
Pfizer Investigational Site
s. Hertogenbosch, Netherlands, 5223 GZ
New Zealand
Pfizer Investigational Site
Auckland, NZ, New Zealand, 0622
Pfizer Investigational Site
Christchurch, New Zealand, 8014
Poland
Pfizer Investigational Site
Bydgoszcz, Poland, 85-796
Pfizer Investigational Site
Kielce, Poland, 25-317
Pfizer Investigational Site
Krakow, Poland, 31-531
Pfizer Investigational Site
Poznan, Poland, 61-289
Pfizer Investigational Site
Warszawa, Poland, 01-211
Pfizer Investigational Site
Warszawa, Poland, 02-097
Portugal
Pfizer Investigational Site
Amadora, Portugal, 2700-276
Pfizer Investigational Site
Coimbra, Portugal, 3000-075
Pfizer Investigational Site
Lisboa, Portugal, 1649-028
Russian Federation
Pfizer Investigational Site
Kazan, Russian Federation, 420101
Pfizer Investigational Site
Nizhny Novgorod, Russian Federation, 603126
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 192019
Pfizer Investigational Site
Saint-Petersburg, Russian Federation, 194044
Serbia
Pfizer Investigational Site
Novi Sad, Vojvodina, Serbia, 21000
Pfizer Investigational Site
Beograd, Serbia, 11000
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 826 06
Pfizer Investigational Site
Bratislava, Slovakia, 820 07
Pfizer Investigational Site
Bratislava, Slovakia, 813 69
Pfizer Investigational Site
Bratislava, Slovakia, 825 56
Pfizer Investigational Site
Martin, Slovakia, 036 59
Pfizer Investigational Site
Michalovce, Slovakia, 071 01
Pfizer Investigational Site
Rimavska Sobota, Slovakia, 979 12
Pfizer Investigational Site
Zilina, Slovakia, 012 07
South Africa
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 2196
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 1709
Pfizer Investigational Site
Pretoria, Gauteng, South Africa, 0081
Pfizer Investigational Site
Durban, Kwa Zulu Natal, South Africa, 4001
Pfizer Investigational Site
Bellville, Western Cape, South Africa, 7530
Pfizer Investigational Site
Panorama, Western Cape, South Africa, 7505
Pfizer Investigational Site
Bellville, South Africa, 7530
Spain
Pfizer Investigational Site
Elche, Alicante, Spain, 03203
Pfizer Investigational Site
Terrassa, Barcelona, Spain, 08221
Pfizer Investigational Site
Plasencia, Caceres, Spain, 10600
Pfizer Investigational Site
Palma de Mallorca, Islas Baleares, Spain, 07010
Pfizer Investigational Site
Palma de Mallorca, Islas Baleares, Spain, 07014
Pfizer Investigational Site
Baracaldo, Spain, 48903
Pfizer Investigational Site
Barcelona, Spain, 08041
Pfizer Investigational Site
Barcelona, Spain, 08034
Pfizer Investigational Site
Barcelona, Spain, 08014
Pfizer Investigational Site
Barcelona, Spain, 08003
Pfizer Investigational Site
Burgos, Spain, 09006
Pfizer Investigational Site
Madrid, Spain, 28034
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
Madrid, Spain, 28041
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
Madrid, Spain, 28006
Pfizer Investigational Site
Murcia, Spain, 30120
Sweden
Pfizer Investigational Site
Malmo, Sweden, 21 224
Pfizer Investigational Site
Uppsala, Sweden, 751 85
Pfizer Investigational Site
Uppsala, Sweden, 751 09
Pfizer Investigational Site
Uppsala, Sweden, 75185
Switzerland
Pfizer Investigational Site
Basel, BS, Switzerland, CH-4031
Pfizer Investigational Site
Les Acacias, GE, Switzerland, 1227
Pfizer Investigational Site
Lausanne, VD, Switzerland, 1005
Pfizer Investigational Site
Thonex-Geneva, Switzerland, CH-1226
United Kingdom
Pfizer Investigational Site
Blackpool, Lancashire, United Kingdom, FY2 0JH
Pfizer Investigational Site
Bradford, West Yorkshire, United Kingdom, BD3 0DQ
Pfizer Investigational Site
Brighton, United Kingdom, BN2 5BE
Pfizer Investigational Site
Glasgow, United Kingdom, G20 0XA
Pfizer Investigational Site
London, United Kingdom, SE5 9RS
Pfizer Investigational Site
London, United Kingdom, W6 8RF
Pfizer Investigational Site
Newcastle upon Tyne, United Kingdom, NE4 5PL
Pfizer Investigational Site
Northampton, United Kingdom, NN1 5BD
Pfizer Investigational Site
Penarth, United Kingdom, CF64 2XX
Pfizer Investigational Site
Sheffield, United Kingdom, S35 8QS
Pfizer Investigational Site
Sheffield, United Kingdom, S10 2JF
Pfizer Investigational Site
Swindon, United Kingdom, SN3 6BW
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00667810     History of Changes
Obsolete Identifiers: NCT00909623
Other Study ID Numbers: 3133K1-3000, B2521001
Study First Received: April 24, 2008
Last Updated: January 8, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
antibody
immunotherapy

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on October 19, 2014